Ultragenyx reports positive interim data from Phase II study of oral sialic acid tablet

Clinical-stage biotechnology company Ultragenyx Pharmaceutical has reported positive interim data from Phase II study of an oral sialic acid extended-release (SA-ER) tablet, UX001, in hereditary inclusion body myopathy (HIBM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news